Our professionals

Imagen del Dr. José Mª Argemí, hepatólogo de la Clínica Universidad de Navarra

Dr. Josepmaría Argemí

Principal Investigator of the Cellular Stress and Immunotherapy in Liver Cancer research group.
Specialist in Internal Medicine.
Primary focus on the study and treatment of liver diseases and hepatic tumors.

Be part of: Cima Universidad de Navarra Clínica Universidad de Navarra Cancer Center Clínica Universidad de Navarra
INDEX H 20

Professional career

Degree in Medicine, University of Barcelona (1997–2003).

Specialist in Internal Medicine, Università Campus Bio-Medico, Rome, Italy (2005–2010).

PhD in Medicine, University of Navarra (2010–2015).

Postdoctoral Fellowship, University of Pittsburgh (2017–2020).

Head of Translational Genomics, Genomics Unit, CIMA, University of Navarra (2020–2023).

Currently serves as Consulting Physician in the Liver Unit of the Internal Medicine Department at the Clínica Universidad de Navarra, Associate Professor at the School of Medicine, University of Navarra, and Adjunct Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh (PA, USA).

RESEARCH AREAS

  • Principal Investigator in the Division of DNA and RNA Medicine at the Center for Applied Medical Research (CIMA), leading the group on Therapeutic Long Non-Coding RNAs and Integrated Stress in Cancer.
  • Associate Researcher at the Biomedical Research Networking Center for Liver and Digestive Diseases (CIBER-EHD) and at the “Digestive System and Metabolism” area of the Navarra Institute for Health Research (IdisNA). Member of the Scientific Committee of the Cancer Center Universidad de Navarra (CCUN).

His basic, translational, and clinical research over the years has focused on liver diseases related to alcohol abuse, liver regeneration, and liver cancer immunotherapy.

Through his research, he has demonstrated the role of cellular stress response systems during liver regeneration. His current work focuses on understanding the cellular stress mechanisms that enable immune evasion by cancer cells, with the goal of developing new strategies to enhance the effectiveness of immunotherapy in liver cancer. He is also involved in several projects and collaborations aimed at identifying predictive biomarkers of response to immune checkpoint inhibitors.

AREAS OF INTEREST

  • Study and treatment of liver diseases from the early stages to liver cirrhosis.
  • Study and treatment of liver tumors.
  • Research on biomarkers of response to immunotherapy.

Activity

In teaching

  • Associate Professor at the School of Medicine, University of Navarra.
  • Teaching in the fields of digestive system pathophysiology and general medical pathology.

In research

  • Co-editor of one educational book and co-author of more than 60 articles published in first-quartile indexed journals, including 22 in the top decile and 8 as lead author in high-impact journals.
  • Co-inventor of two international patents.
  • Co-supervises doctoral theses related to liver cancer.
Imagen de un icono azul con un documento certificado.

Recognition

  • In January 2020 he has been appointed Adjunct Assistant Professor at the University of Pittsburgh (USA), where he continues to make periodic stays to coordinate research projects in genomics applied to hepatology.

Scientific institutions

  • Member of the International Liver Cancer Association (ILCA).
  • Member of the American Association for the Study of Liver Diseases (AASLD).
  • Member of the European Association for the Study of the Liver (EASL).

Latest scientific publications

More information